{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:50:27Z","timestamp":1792511427588,"version":"4.5.0"},"reference-count":40,"publisher":"Bioscientifica","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Anaplastic thyroid cancer (ATC) is an extremely aggressive tumour, with a high mortality rate. Dabrafenib plus trametinib (DT) has significantly impacted the survival of patients with BRAF p.V600E ATC, with noticeable variations in survival between patients. TP53 is frequently mutated in ATC, but its impact on DT response is still unclear. We aimed to investigate the association between TP53 mutational status and clinical outcomes in ATC patients treated with DT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with BRAF-positive ATC (n = 25) treated with DT between 2018 and 2026 were included. Response was assessed by RECIST 1.1. TP53 association with clinicopathological features was evaluated. Four BRAF-mutant cell lines were used: two TP53-mutant (T235 and T238) and two TP53 wild-type (OCUT1 and IHH4).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>TP53 mutations, detected in ATC from 10 patients, were associated with a significantly lower overall survival (6.5 vs 21 months; P &amp;lt; 0.01) and a trend towards shorter progression-free survival (7 vs 19 months; P = 0.09) and duration of response (5.5 vs 9 months; P = 0.09). No significant associations were found between TP53 mutations and sex, primary tumour size, N and M stage, or PI3K pathway alterations. Complementary in vitro experiments across four BRAF p.V600E cell lines provided mechanistic support for these clinical observations, demonstrating that TP53-mutant cells consistently exhibited reduced sensitivity to combined DT therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study suggested that TP53 mutations represent a prognostic factor, associated with worse survival in patients with BRAF p.V600E ATC undergoing DT treatment, highlighting the potential clinical value of incorporating TP53 profiling into patient management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/etj-26-0135","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T09:55:04Z","timestamp":1790848504000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-17","source":"Crossref","is-referenced-by-count":0,"title":["Association of\n                    <i>TP53<\/i>\n                    mutational status and survival in anaplastic thyroid cancer treated with dabrafenib plus trametinib"],"prefix":"10.1530","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1928-4106","authenticated-orcid":true,"given":"Ricardo","family":"Rodrigues","sequence":"first","affiliation":[{"name":"Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG) 1 , ,","place":["Lisboa, Portugal"]},{"name":"NOVA Medical School|Faculdade de Ci\u00eancias M\u00e9dicas da Universidade NOVA de Lisboa 2 , ,","place":["Lisboa, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1958-4531","authenticated-orcid":true,"given":"Tiago Nunes","family":"da Silva","sequence":"additional","affiliation":[{"name":"Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG) 1 , ,","place":["Lisboa, Portugal"]},{"name":"Servi\u00e7o de Endocrinologia, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG) 3 , ,","place":["Lisboa, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9249-3206","authenticated-orcid":true,"given":"Ana","family":"Saramago","sequence":"additional","affiliation":[{"name":"Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG) 1 , ,","place":["Lisboa, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Cavaco","sequence":"additional","affiliation":[{"name":"Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG) 1 , ,","place":["Lisboa, Portugal"]},{"name":"Servi\u00e7o de Endocrinologia, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG) 3 , ,","place":["Lisboa, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saudade","family":"Andr\u00e9","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Anatomia Patol\u00f3gica, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG) 4 , ,","place":["Lisboa, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Dias","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Radiologia, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG) 5 , ,","place":["Lisboa, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0226-5905","authenticated-orcid":true,"given":"Miguel","family":"Rito","sequence":"additional","affiliation":[{"name":"Servi\u00e7o de Anatomia Patol\u00f3gica, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG) 4 , ,","place":["Lisboa, Portugal"]},{"name":"Instituto de Anatomia Patol\u00f3gica, Faculdade de Medicina, Universidade de Lisboa 6 , ,","place":["Lisboa, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5479-7332","authenticated-orcid":true,"given":"Valeriano","family":"Leite","sequence":"additional","affiliation":[{"name":"Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG) 1 , ,","place":["Lisboa, Portugal"]},{"name":"Servi\u00e7o de Endocrinologia, Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG) 3 , ,","place":["Lisboa, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8946-8635","authenticated-orcid":true,"given":"Branca Maria","family":"Cavaco","sequence":"additional","affiliation":[{"name":"Unidade de Investiga\u00e7\u00e3o em Patobiologia Molecular (UIPM), Instituto Portugu\u00eas de Oncologia de Lisboa Francisco Gentil (IPOLFG) 1 , ,","place":["Lisboa, Portugal"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026102011264753400_bib1","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.3390\/cancers14041061","article-title":"Anaplastic thyroid carcinoma: an update","volume":"14","author":"Jannin","year":"2022","journal-title":"Cancers"},{"key":"2026102011264753400_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/thy.2020.0944","article-title":"2021 American Thyroid Association Guidelines for management of patients with anaplastic thyroid cancer","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid"},{"key":"2026102011264753400_bib3","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3390\/cancers11081188","article-title":"Anaplastic thyroid cancer: clinical picture of the last two decades at a single oncology referral centre and novel therapeutic options","volume":"11","author":"Sim\u00f5es-Pereira","year":"2019","journal-title":"Cancers"},{"key":"2026102011264753400_bib4","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1172\/JCI85271","article-title":"Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers","volume":"126","author":"Landa","year":"2016","journal-title":"J Clin Investig"},{"key":"2026102011264753400_bib5","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1089\/thy.2020.0086","article-title":"Dissecting anaplastic thyroid carcinoma: a comprehensive clinical, histologic, immunophenotypic, and molecular study of 360 cases","volume":"30","author":"Xu","year":"2020","journal-title":"Thyroid"},{"key":"2026102011264753400_bib6","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","article-title":"Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers","volume":"24","author":"Pozdeyev","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026102011264753400_bib7","article-title":"Impact of somatic mutations on survival outcomes in patients with anaplastic thyroid carcinoma","volume":"6","author":"Wang","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026102011264753400_bib8","article-title":"Real-world outcomes and prognostic factors in anaplastic thyroid cancer: evidence from the REGETNE-thyroid cohort","volume":"31","author":"Mascar\u00f3-Baselga","year":"2026","journal-title":"Oncologist"},{"key":"2026102011264753400_bib9","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1210\/jc.2017-01180","article-title":"Survival in response to multimodal therapy in Anaplastic thyroid cancer","volume":"102","author":"Prasongsook","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"key":"2026102011264753400_bib10","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1210\/jc.2012-1520","article-title":"A multiinstitutional phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer","volume":"97","author":"Bible","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2026102011264753400_bib11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fonc.2017.00025","article-title":"Lenvatinib for anaplastic thyroid cancer","volume":"7","author":"Tahara","year":"2017","journal-title":"Front Oncol"},{"key":"2026102011264753400_bib12","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1200\/JCO.20.03093","article-title":"Open-label, single-arm, multicenter, phase II trial of lenvatinib for the treatment of patients with anaplastic thyroid cancer","volume":"39","author":"Wirth","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026102011264753400_bib13","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.2017.73.6785","article-title":"Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600\u2013mutant anaplastic thyroid cancer","volume":"36","author":"Subbiah","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026102011264753400_bib14","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.annonc.2021.12.014","article-title":"Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"key":"2026102011264753400_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/ejendo\/lvac011","article-title":"Target therapy for BRAF mutated anaplastic thyroid cancer: a clinical and molecular study","volume":"188","author":"da Silva","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"2026102011264753400_bib16","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/j.clon.2022.10.017","article-title":"Dabrafenib and trametinib therapy for advanced anaplastic thyroid cancer \u2013 real-world outcomes from UK centres","volume":"35","author":"Lorimer","year":"2023","journal-title":"Clin Oncol"},{"key":"2026102011264753400_bib17","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s12020-022-03295-2","article-title":"Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an argentinian experience","volume":"80","author":"Bueno","year":"2023","journal-title":"Endocrine"},{"key":"2026102011264753400_bib18","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.3390\/cancers13194950","article-title":"Rac1 alterations induce acquired dabrafenib resistance in association with anaplastic transformation in a papillary thyroid cancer patient","volume":"13","author":"Bagheri-Yarmand","year":"2021","journal-title":"Cancers"},{"key":"2026102011264753400_bib19","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1089\/thy.2019.0514","article-title":"Acquired secondary RAS mutation in BRAFV600E-mutated thyroid cancer patients treated with BRAF inhibitors","volume":"30","author":"Cabanillas","year":"2020","journal-title":"Thyroid"},{"key":"2026102011264753400_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.592202","article-title":"Perspectives on the treatment of advanced thyroid cancer: approved therapies, resistance mechanisms, and future directions","volume":"10","author":"Porter","year":"2021","journal-title":"Front Oncol"},{"key":"2026102011264753400_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2020.129736","article-title":"Resistance mechanisms to targeted therapy in BRAF-mutant melanoma \u2013 a mini review","volume":"1865","author":"Tangella","year":"2021","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"2026102011264753400_bib22","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.920957","article-title":"A review of the molecular pathways involved in resistance to BRAF inhibitors in patients with advanced-stage melanoma","volume":"26","author":"Tian","year":"2020","journal-title":"Med Sci Monit"},{"key":"2026102011264753400_bib23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2020.03.025","article-title":"Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non\u2013small cell lung cancer","volume":"132","author":"Facchinetti","year":"2020","journal-title":"Eur J Cancer"},{"key":"2026102011264753400_bib24","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1080\/14796694.2024.2340898","article-title":"Dabrafenib-trametinib in BRAF V600-mutated non-small-cell lung cancer: a single center real world experience","volume":"20","author":"Sbrana","year":"2024","journal-title":"Future Oncol"},{"key":"2026102011264753400_bib25","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a001008","article-title":"TP53 mutations in human cancers: origins, consequences, and clinical use","volume":"2","author":"Olivier","year":"2010","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2026102011264753400_bib26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO classification of thyroid neoplasms","volume":"33","author":"Baloch","year":"2022","journal-title":"Endocr Pathol"},{"key":"2026102011264753400_bib27","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3390\/ijms26031035","article-title":"Rationale for testing TP53 mutations in thyroid cancer \u2013 original data and meta-analysis","volume":"26","author":"Lacka","year":"2025","journal-title":"Int J Mol Sci"},{"key":"2026102011264753400_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.surg.2024.05.058","article-title":"Oncogenic mutations in the TP53 and PI-3 kinase\/AKT pathway are independent predictors of survival for advanced thyroid cancer: analysis from the molecular screening and therapeutics (MoST) program","volume":"177","author":"Novis","year":"2025","journal-title":"Surgery"},{"key":"2026102011264753400_bib29","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026102011264753400_bib30","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-18-2953","article-title":"Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies","volume":"25","author":"Landa","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026102011264753400_bib31","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/jmcb\/mjaa040","article-title":"Gain-of-Function mutant P53 in cancer progression and therapy","volume":"12","author":"Zhang","year":"2020","journal-title":"J Mol Cell Biol"},{"key":"2026102011264753400_bib32","doi-asserted-by":"crossref","first-page":"e3353","DOI":"10.1210\/clinem\/dgaf056","article-title":"TP53 alterations associate with poor response to lenvatinib in patients with advanced thyroid cancer","volume":"110","author":"Cirello","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2026102011264753400_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2024.116047","article-title":"TP53R175H mutation promotes breast cancer cell proliferation through CORO1A\u2013P38 MAPK pathway regulation","volume":"221","author":"Su","year":"2024","journal-title":"Biochem Pharmacol"},{"key":"2026102011264753400_bib34","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1172\/JCI120966","article-title":"Hgf\/Met activation mediates resistance to BRAF inhibition in murine anaplastic thyroid cancers","volume":"128","author":"Knauf","year":"2018","journal-title":"J Clin Investig"},{"key":"2026102011264753400_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2026.117078","article-title":"Identification and characterization of BRAF\u21d4TP53 interactions in melanoma","volume":"45","author":"O\u2019Toole","year":"2026","journal-title":"Cell Rep"},{"key":"2026102011264753400_bib36","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1158\/1535-7163.MCT-16-0196","article-title":"TP53 alterations correlate with response to VEGF\/VEGFR inhibitors: implications for targeted therapeutics","volume":"15","author":"Wheler","year":"2016","journal-title":"Mol Cancer Ther"},{"key":"2026102011264753400_bib37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3390\/cancers15020429","article-title":"Drugs targeting P53 mutations with FDA approval and in clinical trials","volume":"15","author":"Nishikawa","year":"2023","journal-title":"Cancers"},{"key":"2026102011264753400_bib38","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.SABCS21-P5-10-03","article-title":"Abstract P5-10-03: mutant P53 and ERK1\/2 MAPK cooperate with the production of TNBC inflammatory secretome","volume":"82","author":"das Neves","year":"2022","journal-title":"Cancer Res"},{"key":"2026102011264753400_bib39","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1200\/JCO.2015.63.3651","article-title":"Biomarker: predictive or prognostic?","volume":"33","author":"Ballman","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026102011264753400_bib40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2217\/pme.09.49","article-title":"Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology","volume":"7","author":"Simon","year":"2010","journal-title":"Per Med"}],"container-title":["European Thyroid Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-26-0135\/525911\/etj-26-0135.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article-pdf\/doi\/10.1530\/ETJ-26-0135\/525911\/etj-26-0135.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:26:55Z","timestamp":1792510015000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/etj\/article\/15\/5\/ETJ260135\/78294\/Association-of-TP53-mutational-status-and-survival"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1530\/etj-26-0135","relation":{},"ISSN":["2235-0802"],"issn-type":[{"value":"2235-0802","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,1]]},"article-number":"ETJ260135"}}